{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:21:10Z","timestamp":1789050070339,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jaci.2023.11.924","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T05:12:55Z","timestamp":1703740375000},"page":"1040-1049.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4R\u03b1, in adults with moderate to severe atopic dermatitis: A\u00a0phase 2 randomized trial (CBP-201-WW001)"],"prefix":"10.1016","volume":"153","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Feinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malinda","family":"Longphre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wubin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selwyn","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7077-7443","authenticated-orcid":false,"given":"Ra\u00fal","family":"Collazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.11.924_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib2","first-page":"108","article-title":"Pathophysiology of atopic dermatitis and psoriasis: implications for management in children","volume":"6","author":"Chovatiya","year":"2019","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jaci.2023.11.924_bib3","doi-asserted-by":"crossref","DOI":"10.5070\/D3258045124","article-title":"The prevalence of atopic dermatitis in adults: systematic review on population studies","volume":"25","author":"Mathiesen","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaci.2023.11.924_bib4","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","article-title":"Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies","volume":"5","author":"Boguniewicz","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.11.924_bib5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jaip.2019.08.030","article-title":"Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study","volume":"8","author":"Schonmann","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.11.924_bib8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bjd.17683","article-title":"Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults","volume":"181","author":"Silverberg","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib9","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3389\/fpsyg.2019.01773","article-title":"Risk of mental disorders in children and adolescents with atopic dermatitis: a systematic review and meta-analysis","volume":"10","author":"Xie","year":"2019","journal-title":"Front Psychol"},{"key":"10.1016\/j.jaci.2023.11.924_bib10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40265-022-01722-2","article-title":"New topical therapies in development for atopic dermatitis","volume":"82","author":"Freitas","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2023.11.924_bib11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council","volume":"77","author":"Simpson","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/187221307780979900","article-title":"Current concept in the treatment of atopic dermatitis","volume":"1","author":"Borlu","year":"2007","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.1016\/j.jaci.2023.11.924_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.anai.2022.03.004","article-title":"Optimizing topical management of atopic dermatitis","volume":"128","author":"Butala","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.11.924_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1203475416685077","article-title":"Review of atopic dermatitis and topical therapies","volume":"21","author":"Mayba","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2023.11.924_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.25259\/IJDVL_1384_20","article-title":"Efficacy of moisturizers in paediatric atopic dermatitis: a systematic review and meta-analysis of randomised controlled trials","volume":"88","author":"Kritsanaviparkporn","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaci.2023.11.924_bib16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1346-8138.15730","article-title":"Current treatments for atopic dermatitis in Japan","volume":"48","author":"Miyano","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-017-0261-5","article-title":"Increasing adherence with topical agents for atopic dermatitis","volume":"18","author":"Patel","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/1744666X.2022.2039122","article-title":"Recent issues in JAK inhibitor safety: perspective for the clinician","volume":"18","author":"Fleischmann","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2023.11.924_bib19","first-page":"6","article-title":"Dermatologic applications and safety considerations of Janus kinase inhibitors","volume":"25","author":"Svoboda","year":"2020","journal-title":"Skin Ther Lett"},{"key":"10.1016\/j.jaci.2023.11.924_bib20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/ijd.15853","article-title":"Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis","volume":"61","author":"Wood","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/ITT.S229667","article-title":"Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis","volume":"9","author":"Singh","year":"2020","journal-title":"ImmunoTargets Ther"},{"key":"10.1016\/j.jaci.2023.11.924_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.11.924_bib24","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.11.924_bib25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/JXX.0000000000000088","article-title":"Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 clinical trials","volume":"30","author":"Tofte","year":"2018","journal-title":"J Am Assoc Nurse Pract"},{"key":"10.1016\/j.jaci.2023.11.924_bib26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Tha\u00e7i","year":"2019","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2023.11.924_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.11.924_bib29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib31","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2018.07.047","article-title":"Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis","volume":"143","author":"Werfel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.11.924_bib32","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.3390\/jcm11206145","article-title":"The dawn of a new era in atopic dermatitis treatment","volume":"11","author":"Yamamura","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2023.11.924_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","article-title":"JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety","volume":"23","author":"Elmariah","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib39","article-title":"Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4R\u03b1, for the treatment of Th2 inflammatory diseases","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2023.11.924_bib40","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/cts.13656","article-title":"Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4R\u03b1: results from two phase 1 randomized trials, in healthy individuals and patients with atopic dermatitis","volume":"16","author":"Wang","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaci.2023.11.924_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-021-00639-y","article-title":"Expert perspectives on key parameters that impact interpretation of randomized clinical trials in moderate-to-severe atopic dermatitis","volume":"23","author":"Silverberg","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib42","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s13555-023-01052-5","article-title":"A mini review of the impact of baseline disease severity on clinical outcomes: should we compare atopic dermatitis clinical trials?","volume":"13","author":"Silverberg","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaci.2023.11.924_bib43","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2019.05.102","article-title":"Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.23736\/S2784-8671.21.06952-2","article-title":"Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index score <24 or \u226524","volume":"157","author":"Offidani","year":"2022","journal-title":"Ital J Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.11.924_bib45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","volume":"85","author":"Simpson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib46","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib47","first-page":"804","article-title":"Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials","volume":"18","author":"Alexis","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaci.2023.11.924_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2023.11.924_bib49","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5114\/ada.2022.117740","article-title":"Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials","volume":"39","author":"Wu","year":"2022","journal-title":"Adv Dermatol Allergol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923025460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923025460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T08:52:55Z","timestamp":1725958375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923025460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0091674923025460"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.11.924","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4R\u03b1, in adults with moderate to severe atopic dermatitis: A\u00a0phase 2 randomized trial (CBP-201-WW001)","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.11.924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}